We provide you with 20 years of free, institutional-grade data for RLAY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RLAY. Explore the full financial landscape of RLAY stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about RLAY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Relay Therapeutics, Inc(NASDAQ:RLAY) 
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small...
Website: http://www.relaytx.com
Full Time Employees: 132
CEO: Sanjiv K. Patel
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends